<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p176" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_176{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_176{left:306px;bottom:30px;}
#t3_176{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_176{left:346px;bottom:30px;}
#t5_176{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_176{left:517px;bottom:30px;}
#t7_176{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_176{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_176{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_176{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_176{left:35px;bottom:777px;letter-spacing:0.11px;word-spacing:0.08px;}
#tc_176{left:35px;bottom:754px;letter-spacing:0.11px;word-spacing:-0.29px;}
#td_176{left:35px;bottom:731px;letter-spacing:0.11px;word-spacing:-0.37px;}
#te_176{left:35px;bottom:707px;letter-spacing:0.06px;word-spacing:-1.1px;}
#tf_176{left:198px;bottom:715px;letter-spacing:0.61px;}
#tg_176{left:211px;bottom:707px;letter-spacing:0.11px;word-spacing:-1.16px;}
#th_176{left:418px;bottom:707px;}
#ti_176{left:428px;bottom:707px;letter-spacing:-0.06px;word-spacing:-0.05px;}
#tj_176{left:35px;bottom:684px;letter-spacing:0.08px;word-spacing:0.1px;}
#tk_176{left:35px;bottom:661px;letter-spacing:0.13px;word-spacing:0.06px;}
#tl_176{left:334px;bottom:668px;letter-spacing:-0.01px;}
#tm_176{left:357px;bottom:661px;letter-spacing:0.13px;word-spacing:0.06px;}
#tn_176{left:35px;bottom:638px;letter-spacing:0.16px;word-spacing:0.03px;}
#to_176{left:35px;bottom:614px;letter-spacing:0.09px;word-spacing:0.1px;}
#tp_176{left:354px;bottom:622px;letter-spacing:0.06px;}
#tq_176{left:422px;bottom:614px;letter-spacing:0.08px;word-spacing:0.11px;}
#tr_176{left:35px;bottom:591px;letter-spacing:0.06px;word-spacing:0.13px;}
#ts_176{left:35px;bottom:568px;letter-spacing:0.09px;word-spacing:0.09px;}
#tt_176{left:35px;bottom:545px;letter-spacing:0.1px;word-spacing:0.09px;}
#tu_176{left:35px;bottom:522px;letter-spacing:0.14px;word-spacing:0.05px;}
#tv_176{left:35px;bottom:498px;letter-spacing:0.05px;word-spacing:0.14px;}
#tw_176{left:35px;bottom:475px;letter-spacing:0.09px;word-spacing:-0.52px;}
#tx_176{left:35px;bottom:436px;letter-spacing:0.31px;}
#ty_176{left:35px;bottom:407px;letter-spacing:0.11px;word-spacing:0.08px;}
#tz_176{left:35px;bottom:383px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t10_176{left:260px;bottom:383px;letter-spacing:0.13px;word-spacing:-0.29px;}
#t11_176{left:35px;bottom:360px;letter-spacing:0.08px;}
#t12_176{left:35px;bottom:318px;letter-spacing:-0.09px;word-spacing:0.95px;}
#t13_176{left:35px;bottom:289px;letter-spacing:0.28px;word-spacing:-0.09px;}
#t14_176{left:35px;bottom:266px;letter-spacing:0.06px;word-spacing:-0.91px;}
#t15_176{left:35px;bottom:243px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t16_176{left:35px;bottom:220px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t17_176{left:35px;bottom:196px;letter-spacing:0.15px;word-spacing:0.04px;}
#t18_176{left:35px;bottom:173px;letter-spacing:0.07px;word-spacing:0.11px;}
#t19_176{left:35px;bottom:134px;letter-spacing:0.32px;word-spacing:-0.13px;}
#t1a_176{left:35px;bottom:105px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1b_176{left:35px;bottom:82px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1c_176{left:35px;bottom:58px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1d_176{left:226px;bottom:58px;letter-spacing:0.23px;word-spacing:-0.04px;}
#t1e_176{left:513px;bottom:58px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1f_176{left:618px;bottom:777px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1g_176{left:983px;bottom:785px;letter-spacing:-0.01px;}
#t1h_176{left:1006px;bottom:777px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1i_176{left:618px;bottom:754px;letter-spacing:0.14px;word-spacing:-0.81px;}
#t1j_176{left:618px;bottom:731px;word-spacing:0.19px;}
#t1k_176{left:618px;bottom:690px;letter-spacing:0.2px;}
#t1l_176{left:618px;bottom:662px;letter-spacing:0.1px;word-spacing:-0.59px;}
#t1m_176{left:618px;bottom:639px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1n_176{left:618px;bottom:616px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1o_176{left:618px;bottom:592px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1p_176{left:618px;bottom:569px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1q_176{left:618px;bottom:546px;letter-spacing:0.3px;word-spacing:-0.11px;}
#t1r_176{left:1041px;bottom:546px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t1s_176{left:618px;bottom:523px;letter-spacing:0.24px;}
#t1t_176{left:726px;bottom:523px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1u_176{left:618px;bottom:500px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1v_176{left:618px;bottom:459px;letter-spacing:0.09px;word-spacing:-0.35px;}
#t1w_176{left:618px;bottom:436px;word-spacing:0.18px;}
#t1x_176{left:618px;bottom:413px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t1y_176{left:749px;bottom:413px;letter-spacing:0.24px;word-spacing:-1.28px;}
#t1z_176{left:963px;bottom:413px;letter-spacing:0.19px;}
#t20_176{left:618px;bottom:390px;letter-spacing:0.03px;word-spacing:0.15px;}
#t21_176{left:618px;bottom:366px;letter-spacing:0.13px;word-spacing:0.06px;}
#t22_176{left:618px;bottom:343px;letter-spacing:0.13px;word-spacing:-0.68px;}
#t23_176{left:618px;bottom:320px;letter-spacing:0.12px;word-spacing:0.07px;}
#t24_176{left:618px;bottom:297px;letter-spacing:0.13px;word-spacing:0.06px;}
#t25_176{left:618px;bottom:273px;letter-spacing:0.12px;word-spacing:-1.17px;}
#t26_176{left:1104px;bottom:273px;letter-spacing:-0.46px;}
#t27_176{left:618px;bottom:250px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t28_176{left:782px;bottom:250px;letter-spacing:0.13px;word-spacing:0.06px;}
#t29_176{left:618px;bottom:227px;letter-spacing:0.12px;word-spacing:-0.71px;}
#t2a_176{left:618px;bottom:204px;letter-spacing:0.02px;word-spacing:0.16px;}
#t2b_176{left:618px;bottom:165px;letter-spacing:0.19px;}
#t2c_176{left:618px;bottom:141px;letter-spacing:0.01px;word-spacing:0.18px;}
#t2d_176{left:809px;bottom:149px;letter-spacing:-0.01px;}
#t2e_176{left:832px;bottom:141px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2f_176{left:618px;bottom:118px;letter-spacing:0.08px;word-spacing:-0.88px;}
#t2g_176{left:618px;bottom:95px;letter-spacing:0.13px;word-spacing:-0.57px;}
#t2h_176{left:618px;bottom:72px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2i_176{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_176{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_176{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_176{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_176{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_176{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_176{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_176{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s7_176{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s8_176{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_176{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts176" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg176Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg176" style="-webkit-user-select: none;"><object width="1210" height="935" data="176/176.svg" type="image/svg+xml" id="pdf176" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_176" class="t s0_176">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_176" class="t s1_176">© </span>
<span id="t3_176" class="t s0_176">(NCCN </span>
<span id="t4_176" class="t s1_176">© </span>
<span id="t5_176" class="t s0_176">), All rights reserved. NCCN Guidelines </span>
<span id="t6_176" class="t s1_176">® </span>
<span id="t7_176" class="t s0_176">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_176" class="t s2_176">NCCN Guidelines Version 4.2024 </span>
<span id="t9_176" class="t s2_176">Head and Neck Cancers </span>
<span id="ta_176" class="t s3_176">MS-35 </span>
<span id="tb_176" class="t s4_176">Based on results from the prospective phase II ECOG-ACRIN Cancer </span>
<span id="tc_176" class="t s4_176">Research Group trial (E3311), de-escalation to 50 Gy may be considered </span>
<span id="td_176" class="t s4_176">in patients with p16-positive oropharynx cancer who have up to 4 positive </span>
<span id="te_176" class="t s4_176">lymph nodes, AJCC 7 </span>
<span id="tf_176" class="t s5_176">th </span>
<span id="tg_176" class="t s4_176">edition N1–2b disease with </span><span id="th_176" class="t s6_176">≤</span><span id="ti_176" class="t s4_176">1 mm ENE, and T1–2 </span>
<span id="tj_176" class="t s4_176">resected to negative or close margins (&lt;3 mm), but this is a category 2B </span>
<span id="tk_176" class="t s4_176">option based on less panel consensus. </span>
<span id="tl_176" class="t s5_176">451 </span>
<span id="tm_176" class="t s4_176">Despite the evidence that RT </span>
<span id="tn_176" class="t s4_176">dose deintensification may improve long-term function while preserving </span>
<span id="to_176" class="t s4_176">PFS in patients with p16-positive disease, </span>
<span id="tp_176" class="t s5_176">444-446,450 </span>
<span id="tq_176" class="t s4_176">more studies are </span>
<span id="tr_176" class="t s4_176">needed in this area. The majority of clinical trials in this space have been </span>
<span id="ts_176" class="t s4_176">single-arm phase 2 and need to be compared to the standard of care in </span>
<span id="tt_176" class="t s4_176">randomized trials. Currently, enrollment of patients with low-risk HPV- </span>
<span id="tu_176" class="t s4_176">positive oropharyngeal cancer is in progress for the randomized phase </span>
<span id="tv_176" class="t s4_176">II/III NRG HN-005 trial, which will compare deescalated 60 Gy with </span>
<span id="tw_176" class="t s4_176">cisplatin, 60 Gy with nivolumab, and 70 Gy with cisplatin (NCT03952585). </span>
<span id="tx_176" class="t s3_176">Follow-up/Surveillance </span>
<span id="ty_176" class="t s4_176">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="tz_176" class="t s7_176">Follow-up Recommendations </span><span id="t10_176" class="t s4_176">in the NCCN Guidelines for Head and Neck </span>
<span id="t11_176" class="t s4_176">Cancers). </span>
<span id="t12_176" class="t s8_176">Cancer of the Hypopharynx </span>
<span id="t13_176" class="t s4_176">The hypopharynx extends from the superior border of the hyoid bone to </span>
<span id="t14_176" class="t s4_176">the lower border of the cricoid cartilage and is essentially a muscular, lined </span>
<span id="t15_176" class="t s4_176">tube extending from the oropharynx to the cervical esophagus. For staging </span>
<span id="t16_176" class="t s4_176">purposes, the hypopharynx is divided into three areas: 1) the pyriform </span>
<span id="t17_176" class="t s4_176">sinus (the most common site of cancer in the hypopharynx); 2) the </span>
<span id="t18_176" class="t s4_176">posterior pharyngeal walls; and 3) the postcricoid area. </span>
<span id="t19_176" class="t s3_176">Workup and Staging </span>
<span id="t1a_176" class="t s4_176">A multidisciplinary consultation is encouraged. Accurate staging (see </span>
<span id="t1b_176" class="t s4_176">Table 3) depends on a complete H&amp;N examination coupled with </span>
<span id="t1c_176" class="t s4_176">appropriate studies (see </span><span id="t1d_176" class="t s7_176">Cancer of the Hypopharynx: Workup </span><span id="t1e_176" class="t s4_176">in the </span>
<span id="t1f_176" class="t s4_176">NCCN Guidelines for Head and Neck Cancers). </span>
<span id="t1g_176" class="t s5_176">391 </span>
<span id="t1h_176" class="t s4_176">For patients with </span>
<span id="t1i_176" class="t s4_176">cancer of the hypopharynx, the prognosis can be poor despite aggressive </span>
<span id="t1j_176" class="t s4_176">combined modality treatment. </span>
<span id="t1k_176" class="t s3_176">Treatment </span>
<span id="t1l_176" class="t s4_176">Patients with resectable disease are divided into two groups based on the </span>
<span id="t1m_176" class="t s4_176">indicated surgical options: 1) those with early-stage cancer who are </span>
<span id="t1n_176" class="t s4_176">amenable to larynx-preserving (conservation) surgery (most T1, N0; </span>
<span id="t1o_176" class="t s4_176">selected T2, N0); and 2) those with advanced resectable cancer who </span>
<span id="t1p_176" class="t s4_176">require pharyngectomy with total or partial laryngectomy (T1–4a, any N). </span>
<span id="t1q_176" class="t s4_176">The surgery and RT options for the former group (see </span><span id="t1r_176" class="t s7_176">Cancer of the </span>
<span id="t1s_176" class="t s7_176">Hypopharynx </span><span id="t1t_176" class="t s4_176">in the NCCN Guidelines for Head and Neck Cancers) </span>
<span id="t1u_176" class="t s4_176">represent a consensus among the panel members. </span>
<span id="t1v_176" class="t s4_176">Patients with T1–3, any N disease, for whom the indicated surgical option </span>
<span id="t1w_176" class="t s4_176">is partial or total laryngopharyngectomy, may be managed with three </span>
<span id="t1x_176" class="t s4_176">approaches (see </span><span id="t1y_176" class="t s7_176">Cancer of the Hypopharynx </span><span id="t1z_176" class="t s4_176">in the NCCN Guidelines for </span>
<span id="t20_176" class="t s4_176">Head and Neck Cancers) in addition to enrollment in clinical trials: 1) </span>
<span id="t21_176" class="t s4_176">induction chemotherapy followed by additional treatment, depending on </span>
<span id="t22_176" class="t s4_176">the response; 2) surgery with neck dissection(s), and postoperative RT or </span>
<span id="t23_176" class="t s4_176">chemoradiation as dictated by pathologic risk features; or 3) concurrent </span>
<span id="t24_176" class="t s4_176">systemic therapy/RT. When using concurrent systemic therapy/RT, the </span>
<span id="t25_176" class="t s4_176">preferred systemic agent is high-dose cisplatin (category 1) (see </span><span id="t26_176" class="t s7_176">Principles </span>
<span id="t27_176" class="t s7_176">of Systemic Therapy </span><span id="t28_176" class="t s4_176">in the NCCN Guidelines for Head and Neck </span>
<span id="t29_176" class="t s4_176">Cancers). Given the overall poor prognosis for advanced hypopharyngeal </span>
<span id="t2a_176" class="t s4_176">cancer, participation in clinical trials is encouraged. </span>
<span id="t2b_176" class="t s4_176">The option of the induction chemotherapy/definitive RT is based on an </span>
<span id="t2c_176" class="t s4_176">EORTC randomized trial. </span>
<span id="t2d_176" class="t s5_176">290 </span>
<span id="t2e_176" class="t s4_176">This trial enrolled 194 eligible patients with </span>
<span id="t2f_176" class="t s4_176">stage II–IV resectable squamous cell carcinoma of the pyriform sinus (152 </span>
<span id="t2g_176" class="t s4_176">patients) and aryepiglottic fold (42 patients), excluding patients with T1 or </span>
<span id="t2h_176" class="t s4_176">N2c disease. Patients were randomly assigned either to </span>
<span id="t2i_176" class="t s9_176">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
